Livzon Pharmaceutical (HKG:1513, SHE:000513) recorded a 9.4% rise in attributable profit in the first half of 2025 to 1.28 billion yuan from 1.17 billion yuan in the year-ago period, a Wednesday Hong Kong bourse filing said.

The pharmaceutical firm's earnings per share were 1.43 yuan in the half year, up from 1.27 yuan in the corresponding period of the last year.

Operating income fell 0.2% to 6.27 billion yuan in the interim period from 6.28 billion yuan a year prior.